Bosentan for chronic thromboembolic pulmonary hypertension: Findings from a systematic review and meta-analysis

Thrombosis Research

Volumn 126, Issue 1, 2010, Pages

  Becattini, Cecilia ^a   Manina, Giorgia ^a   Busti, Chiara ^a   Gennarini, Silvia ^a   Agnelli, Giancarlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ANTIHYPERTENSIVE AGENT; SULFONAMIDE;

ARTICLE; CASE CONTROL STUDY; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; EXERCISE; HEART INDEX; HEART RIGHT VENTRICLE FAILURE; HUMAN; LIVER FUNCTION; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; MEDLINE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; CHRONIC DISEASE; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEMODYNAMICS; HYPERTENSION; HYPERTENSION, PULMONARY; PATHOPHYSIOLOGY; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VASCULAR RESISTANCE;

ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; CHRONIC DISEASE; COHORT STUDIES; DOUBLE-BLIND METHOD; HEMODYNAMICS; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 77953123410     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.01.007     Document Type: Article

References (29)

1. Pengo V., Lensing A.W., Prins M.H., Marchiori A., Davidson B.L., Tiozzo F., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350 (2004) 2257-2264
2. Hoeper M.M., Mayer E., and Simonneau G. Chronic thromboembolic pulmonary hypertension. Circulation 113 (2006) 2011-2020
3. Fedullo P.F., Auger W.R., Channick R.N., Moser K.M., and Jamieson S.W. Chronic thromboembolic pulmonary hypertension. Clin Chest Med 16 (1995) 353-47
4. Riedel M., Stanek V., Widimsky J., and Prerovsky I. Longterm follow- up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest 81 (1982) 151-158
5. Moser K.M., Auger W.R., and Fedullo P.F. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 81 (1990) 1735-1743
6. Kunieda T., Nakanishi N., Satoh T., Kyotani S., Okano Y., and Nagaya N. Prognoses of primary pulmonary hypertension and chronic major vessel thromboembolic pulmonary hypertension determined from cumulative survival curves. Intern Med 38 (1999) 543-546
7. Moher D., Pham B., Jones A., Cook D.J., Jadad A.R., Moher M., et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 352 (1998) 609-613
8. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 (1999) 1896-1900
9. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000) 2008-2012
10. Bland J.M., and Kerry S.M. Statistics notes. Weighted comparison of means. BMJ 316 (1998) 129
11. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
12. Altman D.G., Chalmers I., Egger M., et al. Systematic Reviews in health care: meta-analysis in context. 2nd ed (2001), Blackwell BMJ, London UK
13. Higgins J.P.T., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
14. Jaïs X., D'Armini A.M., Jansa P., Torbicki A., Delcroix M., Ghofrani H.A., et al. Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): A randomized, placebo-controlled trial - BENEFiT. J Am Coll Cardiol 52 (2008) 2127-2134
15. Vassallo F.G., Kodric M., Scarduelli C., Harari S., Potena A., Scarda A., et al. Bosentan for patients with chronic thromboembolic pulmonary hypertension. Eur J Intern Med 20 (2009) 24-29
16. Sharma S., Kashour T., and Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex Heart Inst J 32 (2005) 405-410
17. Suntharalingam J., Hodgkins D., Cafferty F.H., Hughes R.J., and Pepke-Zaba J. Does rapid dose titration affect the hepatic safety profile of Bosentan?. Vascul Pharmacol 44 (2006) 508-512
18. George P, Hodgkins D, Morrell N, Pepke-Zaba J. Open label study of bosentan in chronic thromboembolic pulmonary hypertension. ERS 2004 Abstract 4332.
19. Hughes R.J., Jais X., Bonderman D., Suntharalingam J., Humbert M., Lang I., et al. The efficacy of Bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1 year follow-up study. Eur Respir J 28 (2006) 138-143
20. Román A., Gispert P., Monforte V., Bravo C., Domingo E., and Morell F. Long-term outcomes of treatment with bosentan in pulmonary hypertension. Arch Bronconeumol 42 (2006) 616-620
21. Beyer S., Speich R., Fischler M., Maggiorini M., and Ulrich S. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. Swiss Med Wkly 136 (2006) 114-118
22. Seyfarth H.J., Pankau H., Hammerschmidt S., Schauer J., Wirtz H., and Winkler J. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 128 (2005) 709-713
23. Hoeper M.M., Kramm T., Wilkens H., Schulze C., Schäfers H.J., Welte T., et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128 (2005) 2363-2367
24. Cubero J.S., Uribe J.C.O., Bueno M.G., Palomero V.M., González M.G., and Rivera L.A.P. Efectividad del bosentán en el tratamiento de la hipertensión pulmonar debida a tromboembolia venosa crónica. Med Clin (Barc) 128 (2007) 12-14
25. Seyfarth H.J., Hammerschmidt S., Pankau H., Winkler J., and Wirtz H. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration 74 (2007) 287-292
26. Ulrich S., Speich R., Domenighetti G., Geiser T., Aubert JD., T. S., et al. Bosentantherapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med Wkly 137 (Oct 20 2007) 573-580
27. Bondermann D., Nowotny R., Skoro-Sajer N., Jakowitsch J., Adlbrecht C., Klepetko W., et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128 (2005) 2599-2603
28. Thistlethwaite P.A., Mo M., Madani M.M., Deutsch R., Blanchard D., Kapelanski D.P., et al. Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg 124 (2002) 1203-1211
29. Sitbon O., Badesch D.B., Channick R.N., Frost A., Robbins I.M., Simonneau G., et al. Effect of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1 year follow-up study. Chest 124 (2003) 247-254